Haoxi Health Technology Limited Announces Closing of $9,600,000 Initial Public Offering
31 January 2024 - 8:05AM
Haoxi Health Technology Limited (the “Company” or “HAO”), an online
marketing solution provider headquartered in Beijing, China, today
announced the closing of its initial public offering (the
"Offering") of 2,400,000 Class A ordinary shares (the "Ordinary
Shares") at an initial public offering price of $4.00 per share for
total gross proceeds of $9,600,000, before deducting underwriting
discounts and other offering expenses. The Offering closed on
January 30, 2024, and the Ordinary Shares began trading on Nasdaq
Capital Market on January 26, 2024, under the ticker symbol "HAO".
The Company has granted EF Hutton LLC (“EF Hutton”), the
representative of the underwriters, an option, within 45 days from
the closing date of the Offering, to purchase up to an additional
360,000 Ordinary Shares at the public offering price, less
underwriting discounts, to cover the over-allotments, if any. The
Offering has been conducted on a firm commitment basis.
EF Hutton acted as the sole bookrunner for the Offering. Hunter
Taubman Fischer & Li LLC acted as U.S. counsel to the Company,
and Pryor Cashman LLP acted as U.S. counsel to EF Hutton, in
connection with the Offering.
The Company intends to use the proceeds from this Offering for
1) working capital and general corporate purposes; 2) acquiring or
investing in technologies, solutions, or businesses; and 3) hiring
experienced employees.
The registration statement on Form F-1 (File No. 333-274214)
relating to the Offering, as amended, was filed with the U.S.
Securities and Exchange Commission (the "SEC") initially on August
25, 2023, and was declared effective by the SEC on January 25,
2024. The Offering was made only by means of a prospectus. Copies
of the final prospectus related to the Offering may be obtained,
from EF Hutton, Attn: Syndicate Department, 590 Madison Avenue,
39th Floor, New York, NY 10022, or via email at
syndicate@efhutton.com or telephone at (212) 404-7002. In addition,
a copy of the final prospectus can also be obtained via the SEC’s
website at www.sec.gov.
Before you invest, you should read the prospectus and other
documents the Company has filed or will file with the SEC for more
information about the Company and the Offering. This press release
shall not constitute an offer to sell or the solicitation of an
offer to buy the securities described herein, nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Haoxi Health Technology Limited
Haoxi Health Technology Limited is a Beijing-headquartered
online marketing solution provider in China, specializing in
serving healthcare industry advertiser clients. The Company’s
growth is driven by the rise of news feed ads and the rapid
development of the healthcare sector. The Company offers one-stop
online marketing solutions, especially in online short video
marketing, helping advertisers acquire and retain customers on
popular platforms in China, such as Toutiao, Douyin, WeChat, and
Sina Weibo. It is dedicated to reducing costs, increasing
efficiency, and providing easy online marketing solutions to
advertisers. For more information, please visit:
http://ir.haoximedia.com.
Forward-Looking Statement
This press release contains forward-looking statements.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may," "will," "intend," "should," "believe," "expect,"
"anticipate," "project," "estimate" or similar expressions that do
not relate solely to historical matters, it is making
forward-looking statements. Forward-looking statements are not
guarantees of future performance and involve risks and
uncertainties that may cause the actual results to differ
materially from the Company's expectations discussed in the
forward-looking statements. These statements are subject to
uncertainties and risks including, but not limited to, the
uncertainties related to market conditions and the completion of
the initial public offering on the anticipated terms or at all, and
other factors discussed in the “Risk Factors” section of the
registration statement filed with the SEC. For these reasons, among
others, investors are cautioned not to place undue reliance upon
any forward-looking statements in this press release. Additional
factors are discussed in the Company's filings with the SEC, which
are available for review at www.sec.gov. The Company undertakes no
obligation to publicly revise these forward-looking statements to
reflect events or circumstances that arise after the date
hereof.
For more information, please contact:
Representative of the underwritersEF Hutton LLCMs. Stephanie Hu,
Head of Asia, Investment
BankingEmail:syndicate@efhutton.com
Investor Relations
WFS Investor Relations Inc.Janice Wang, Managing PartnerEmail:
services@wealthfsllc.com Phone: +86 13811768599+1 628 283
9214
Haoxi Health Technology (NASDAQ:HAO)
Historical Stock Chart
From Dec 2024 to Jan 2025
Haoxi Health Technology (NASDAQ:HAO)
Historical Stock Chart
From Jan 2024 to Jan 2025